Fed’s Powell opens door to potential rate cuts at Jackson Hole
Dario Scimeca, the General Counsel and Secretary of Precision BioSciences Inc . (NASDAQ:DTIL), recently executed a series of transactions involving the company’s common stock. According to a filing with the Securities and Exchange Commission, Scimeca sold 272 shares of Precision BioSciences stock on March 4, 2025, at a price of $4.91 per share, totaling approximately $1,335. The transaction comes as the stock, currently trading at $5.24, has experienced significant volatility, declining 47% over the past six months. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available to subscribers.
On March 3, 2025, Scimeca also acquired 919 shares of common stock through the vesting of Restricted Stock Units (RSUs), which were granted earlier. These RSUs converted to common stock at no cost. The sale of shares the following day was conducted under a Rule 10b5-1 plan, with the sole purpose of covering tax withholding obligations associated with the RSU vesting. Following these transactions, Scimeca holds 25,000 shares of Precision BioSciences common stock, representing a notable stake in the $40.16M market cap company. Investors should note that DTIL is scheduled to report earnings in 7 days, which could impact stock performance.
In other recent news, Precision BioSciences reported promising results from its gene editing trials. The company announced preliminary data from the ELIMINATE-B study targeting chronic hepatitis B, showing substantial antiviral activity and a favorable safety profile. Additionally, in collaboration with iECURE, the company achieved a complete clinical response in the first infant treated in a Phase 1/2 trial for Ornithine Transcarbamylase deficiency. This success has led BMO Capital to upgrade Precision BioSciences from Market Perform to Outperform, citing a favorable risk/reward profile and setting a price target of $34.00.
H.C. Wainwright also maintained a Buy rating on the company, with a price target of $60.00, following the positive trial outcomes. Precision BioSciences’ financial update reveals an estimated $108.5 million in cash as of December 2024, with expectations to sustain operations into the second half of 2026. The company received an additional $2.5 million from TG Therapeutics (NASDAQ:TGTX), which will support ongoing and future clinical trials. In corporate governance news, Dr. Sam Wadsworth announced his retirement from the Board of Directors, effective January 2025, with no immediate impact on company operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.